Table 1.
Characteristics of 197 patients with 11q deletion with respect to the number of losses detected by FISH: <40% (n = 51) or ≥40% (n = 146).
Table 2.
Multivariate Cox regression analysis of time to first therapy in 11q- CLL patients with respect to the number of losses detected by FISH: <40% (n = 51) or ≥40% (n = 146).*
Fig 1.
(A) Time to first therapy (TFT) and (B) overall survival (OS) of 197 patients with 11q deletion CLL and <40% or ≥40% FISH losses.
Table 3.
Multivariate Cox regression analysis of overall survival in 11q- CLL patients with respect to the number of losses detected by FISH: <40% (n = 51) or ≥40% (n = 146).*
Fig 2.
Localization and frequencies of mutations in ATM, SF3B1, NOTCH1, TP53, XPO1 and BIRC3 genes.
Mutations are indicated at the amino-acid level; each detected alteration is represented by a dot. Mutation type is represented by a dark (missense), white (nonsense) or grey (frameshift) dot. The sequenced exons for each gene are represented with a grey line below each schematic protein organization.
Table 4.
ATM mutations in 25 CLL patients with del(11q).
Table 5.
Mutations in other genes in 25 CLL patients with del(11q).
Fig 3.
Distribution of mutations of ATM, SF3B1, NOTCH1, TP53, XPO1 and BIRC3 among 11q- CLL patients with respect to the percentage of 11q- cells.
In the heat maps, rows correspond to identical genes, and columns represent individual patients color-coded on the basis of gene status (white: wild type; grey: mutated gene).